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Abstract
Background: The endocannabinoids, anandamide and 2-AG, are produced by adipocytes, where they stimulate 
lipogenesis via cannabinoid CB1 receptors and are under the negative control of leptin and insulin. Endocannabinoid 
levels are elevated in the blood of obese individuals and nonobese type 2 diabetes patients. To date, no study has 
evaluated endocannabinoid levels in subcutaneous adipose tissue (SAT) of subjects with both obesity and type 2 
diabetes (OBT2D), characterised by similar adiposity and whole body insulin resistance and lower plasma leptin levels 
as compared to non-diabetic obese subjects (OB).
Design and Methods: The levels of anandamide and 2-AG, and of the anandamide-related PPARα ligands, 
oleoylethanolamide (OEA) and palmitoylethanolamide (PEA), in the SAT obtained by abdominal needle biopsy in 10 
OBT2D, 11 OB, and 8 non-diabetic normal-weight (NW) subjects, were measured by liquid chromatography-mass 
spectrometry. All subjects underwent a hyperinsulinaemic euglycaemic clamp.
Results: As compared to NW, anandamide, OEA and PEA levels in the SAT were 2-4.4-fold elevated (p < 0.05), and 2-AG 
levels 2.3-fold reduced (p < .05), in OBT2D but not in OB subjects. Anandamide, OEA and PEA correlated positively (p < 
.05) with SAT leptin mRNA and free fatty acid during hyperinsulinaemic clamp, and negatively with SAT LPL activity and 
plasma HDL-cholesterol, which were all specifically altered in OBT2D subjects.
Conclusions: The observed alterations emphasize, for the first time in humans, the potential different role and 
regulation of adipose tissue anandamide (and its congeners) and 2-AG in obesity and type 2 diabetes.
Background
The endocannabinoid system (ECS), composed of G-pro-
tein-coupled cannabinoid receptors of type 1 and 2 (CB1
and CB2), of endogenous ligands for such receptors, the
endocannabinoids arachidonoylethanolamide (anand-
amide, AEA) and 2-arachidonoylglycerol (2-AG), and of
enzymes catalysing endocannabinoid biosynthesis and
degradation, is a key player in the control of metabolism
at both central and peripheral levels [1]. In the hypothala-
mus, endocannabinoids acting at CB1 receptors modulate
the circuitries involved in food intake and are under the
negative control of leptin [2]. In the white adipose tissue
(WAT), the ECS stimulates lipogenesis and inhibits lipol-
ysis via several mechanisms, and is under the negative
control of either leptin or PPARγ [1,3-5]. PPARγ agonists,
such as the glitazones, used for the treatment of type 2
diabetes (T2D), reduce either adipocyte 2-AG concentra-
tions or CB1 receptor expression levels, or both [3-5].
Insulin also acts as a negative modulator of endocannabi-
noid levels in both human and murine WAT [3,6,7].
Plasma endocannabinoid levels, which likely reflect to a
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Page 2 of 8large extent the "spill-over" of these lipid mediators from
peripheral organs, are decreased postprandially or fol-
lowing oral glucose load and euglycaemic hyperinsulinae-
mic clamp in lean [3,8], but not in insulin resistant obese
subjects [8], who, like T2D patients, show higher levels of
endocannabinoids also when fasting [3-7,9].
In abdominally obese individuals, blood 2-AG, but not
AEA, concentrations correlate directly with the amount
of visceral adipose tissue (VAT) and blood triacylglycer-
ols (TGs), and inversely with HDL-cholesterol levels
[10,11], and such correlations are also observed between
the changes in blood 2-AG levels and those in TG and
HDL-cholesterol levels induced by a lifestyle intervention
leading to a strong reduction of waist circumference and
VAT [12]. In experimental models of obesity, higher levels
of endocannabinoids are found also in the visceral (e.g.
epididymal) vs. subcutaneous adipose depots [3,13,14].
This dysregulation of endocannabinoid tone in the WAT
is probably due, at least in part, to dysfunctional expres-
sion of endocannabinoid metabolising enzymes. In fact, a
lower expression of the fatty acid amide hydrolase
(FAAH), which can metabolise both AEA and 2-AG, as
well as other congeners of AEA (see below), or of the
monoacylglycerol lipase (MAGL), which is more specific
for 2-AG [15], has been reported in the VAT of obese
individuals [10,16], possibly accounting for the observed
higher VAT levels of 2-AG [3]. As opposed to obese
rodents [13], reduced levels of FAAH expression have
been reported for obese subjects also in the subcutaneous
adipose tissue (SAT) [9,16,17], where, instead, there
seems to be no elevation of endocannabinoid levels [3].
However, no such studies have been performed to date in
the WAT of obese patients with type 2 diabetes, who can
be characterised by similar whole body insulin resistance,
but lower plasma leptin levels, as compared to matched
non diabetic obese subjects [18,19].
The SAT plays an important role as a buffer against
ectopic lipid accumulation and the subsequent increased
inflammatory profile typical of abdominally obese
patients [20]. Therefore, in view of the prolipogenic role
of the ECS in the WAT, a higher endocannabinoid tone in
SAT might be regarded as protective towards the meta-
bolic consequences of obesity, whereas a reduced tone
might contribute to these consequences. For this reason,
and also to acquire some unprecedented information on
endocannabinoid tone in the WAT of subjects with T2D,
we have compared here the levels of AEA and 2-AG in
the SAT of age- and gender-matched T2D obese
(OBT2D), obese only (OB), and normal weight (NW) vol-
unteers. Furthermore, since two cannabinoid receptor-
inactive and metabolically-related AEA congeners,
oleoylethanolamide (OEA) and palmitoylethanolamide
(PEA), which are also degraded by FAAH, are emerging
as potent endogenous ligands of peroxisome proliferator-
activated receptor α (PPARα), a well established target for
the therapy of dyslipidemia [21], and were recently found
to be dysregulated in obese Zucker rats [22], we have also
measured the SAT levels of these two lipid mediators.
Methods and subjects
Subjects
Ten patients with type 2 diabetes mellitus and obesity
(OBT2D), 11 patients with only obesity (OB), and 8 nor-
mal-weight control subjects (NW) participated in the
study. Their baseline characteristics are shown in Table 1.
All subjects had normal fasting plasma concentration of
both triglyceride (<1.7 mmol/l) and cholesterol (<5.5
mmol/l). The subjects had no history or symptoms of any
known disease, apart from diabetes, nor were they vege-
tarians or engaged in intensive physical activity. They
were not taking any hypolipidaemic drug. Diabetic
patients were in stable glycaemic control on diet alone
(HbA1c = 6.5 ± 0.5%). The study protocol was approved
by the Federico II University Ethics Committee and
informed consent by the participants was obtained.
Experimental procedures
In the morning, after a 12-14 hr fast, following an evening
meal based on the usual diet, anthropometric measure-
ments, according to standardized procedures, and blood
samples were drawn. Thereafter, a needle biopsy of the
abdominal subcutaneous adipose tissue was taken under
local anaesthesia with lidocaine, and a hyperinsulinaemic
euglycaemic clamp was performed (120 min insulin infu-
sion 1.5 mU·kg body weight-1·min-1) [18]. Advice was
given to have the meal at the proper time, and to avoid
alcohol intake. Compliance was assessed by a 3-day food
diary filled in by the participants. The subjects were also
requested to avoid moderate/strenuous physical activity
on the 3 days before the experiment.
Extraction and quantification of endocannabinoids and 
related lipids
Frozen SAT tissue samples were homogenized in chloro-
form/methanol/TRIS-HCl 50 mM pH 7.4 (2:1:1, v/v) con-
taining 10 pmol of [2H]8-AEA, [2H]4-PEA and [2H]4-
OEA, and 50 pmol of [2H]5-2-AG as internal deuterated
standards (purchased from Cayman Chemicals, Ann
Arbor, MI). The extract was purified by means of silica
gel mini-columns, and the eluted fraction containing
AEA and 2-AG analysed by means of liquid chromatogra-
phy-atmospheric pressure-mass spectrometry (LC-
APCI-MS) conducted as described previously [23]. Anal-
yses were carried out in the selected ion-monitoring
mode using m/z values of 356 and 348 (molecular ions +1
for deuterated and undeuterated AEA), 304 and 300
(molecular ions +1 for deuterated and undeuterated
PEA), 330 and 326 (molecular ions +1 for deuterated and
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ions +1 for deuterated and undeuterated 2-AG). AEA,
OEA, PEA and 2-AG concentrations were calculated by
isotope dilution and are expressed as pmol per g of wet
tissue weight. The concentrations of 2-AG were obtained
by adding up to the amounts of the 2-isomer also those of
the 1(3)-isomer, which mostly originates from the
isomerization of the former during work-up.
Other measurements
Plasma cholesterol and triglyceride concentrations were
assayed by enzymatic colorimetric methods (Roche Diag-
nostics, Milan, Italy). Plasma leptin concentrations were
assayed using a competitive ELISA (BioVendor Labora-
tory Medicine, Brno, Czech Republic). Plasma insulin
concentrations were measured by ELISA (Technogenet-
ics, Milan, Italy).
Table 1: Clinical characteristics and metabolic measurements in plasma and adipose tissue of the subjects participating in 
the study.
Diabetes + obesity Obesity Control
Males (n) 10 11 8
Age (years) 47 [8] 47 [20] 38 [9]
BMI (kg/m2) 33.4 [2.4] ** 34.5 [2.7] ** 23.8 [1.2]
Waist circumference (cm) 111.4 [7.7] ** 113.1 [6.7] ** 84.9 [4.4]
Plasma cholesterol (mg/dl) 171.8 [25.9] 194.1 [29.9] 166.7 [24.2]
Plasma triglyceride (mg/dl) 111.2 [54.7] 99.8 [34.7] 72.4 [28.2]
LDL cholesterol (mg/dl) 102.1 [19.6] 114.9 [26.4] 96.8 [14.6]
HDL cholesterol (mg/dl) 34.5 [5.8] *§ 44.3 [10.3] 47.7 [10.6]
Plasma glucose (mg/dl) 132.7 [37.2] *§ 87.9 [13.9] 87.2 [9.9]
Plasma insulin (mU/l) 14.3 [6.4] 15.6 [4.2] 6.4 [1.5]
Plasma leptin (ng/ml) 9.4 [4.2]§ 24.9 [9.6]** 5.4 [2.3]
Adipose tissue leptin mRNA 
(AU)
2.62 [1.90] * 1.73 [1.82] 0.77 [0.38]
Adipose tissue LPL activity
(nmol fatty acids/g tissue)
105 [45] *§ 231 [128] 251 [119]
Insulin sensitivity (M-value) 
(mg/kg/min)
4.55 [1.41] ** 4.63 [1.48] ** 8.13 [2.32]
FFA during hyperinsulinaemic 
clamp (μmol/l)
84.0 [50.8] * 73.0 [33.7] * 36.2 [7.4]
Data are expressed as M [SD]. ANOVA and LSD (Kruskal-Wallis for plasma triglyceride, LPL activity, and leptin RNA) * p < 0.05, ** p < 0.001 vs 
Control, §p < 0.05 vs Obesity. AU = arbitrary units, LPL = lipoprotein lipase.
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determined as previously described [24]. The expression
of leptin mRNA was evaluated by RT-PCR [25]. The spe-
cific primers to amplify leptin (Acc.U43653) were sense:
5'-ATG CAT TGG GGA ACC CTG TGC GG-3'and anti-
sense: 5'-AGG TCC AGC TGC CAC AGC ATG TC-3'
(487 bp). Results are expressed as the ratio between the
leptin gene and GAPDH in each sample analyzed.
Statistical analyses
Data are expressed as mean ± standard deviation (M ±
SD), unless otherwise stated. Differences between the
three groups (OBT2D, OB and NW) were evaluated by
ANOVA and by post hoc test between groups (LSD). The
relationship between endocannabinoid levels and meta-
bolic measurements was assessed by Pearson correlation.
Variables not normally distributed were analyzed by a
nonparametric test (Kruskal-Wallis ANOVA). Two-tailed
tests were used and a p < 0.05 was considered statistically
significant. Statistical analysis was performed according
to standard methods using the Statistical Package for
Social Sciences software (SPSS/PC, SPSS, Inc., Chicago,
IL).
Results
Anthropometrics and metabolic measurements
Obese subjects with and without diabetes had similarly
high BMI and abdominal circumferences compared with
NW controls (Table 1). As expected, blood glucose levels
were significantly higher in OBT2D group compared to
the other two groups. Fasting plasma insulin levels were
significantly higher in both groups of obese with and
without diabetes compared to NW.
Insulin sensitivity measured by euglycaemic hyperinsu-
linaemic clamp and expressed as M-value was similarly
lower in the two obese groups compared to NW controls.
Insulin antilipolytic activity, expressed by plasma FFA
level inhibition during the hyperinsulinaemic clamp, was
impaired in the OBT2D subjects compared to the other
two groups.
Fasting plasma leptin levels where highest, intermedi-
ate and lowest in OB, OBT2D and NW subjects, respec-
tively, while leptin mRNA in adipose tissue tended to be
higher in OBT2D than in NW. Heparin-releasable LPL
activity, expressed per gram of adipose tissue, was signifi-
cantly lower in the OBT2D subjects compared to the
other two groups.
Adipose tissue endocannabinoid levels
As shown in Fig. 1, the SAT concentrations of AEA, OEA
and PEA were significantly higher in OBT2D than in
either OB or NW subjects. By contrast, 2-AG concentra-
tions were significantly lower in OBT2D than in either
OB or NW subjects. No significant differences were
observed between the concentrations of these four com-
pounds in the SAT of OB and NW subjects.
In the three groups combined, OEA and PEA concen-
trations in the SAT correlated positively with each other
and with AEA, whereas no correlation was found
between AEA, OEA or PEA levels and 2-AG (Table 2).
AEA, OEA and PEA levels were positively correlated with
plasma FFA during hyperinsulinaemic clamp and SAT
leptin RNA; and negatively correlated with HDL choles-
terol and adipose tissue LPL activity. Adipose tissue 2-AG
levels were positively correlated with M-value.
Discussion
In the present study we have measured for the first time
the concentrations of two cannabinoid receptor agonists,
AEA and 2-AG, and two AEA-related PPAR-α activators,
OEA and PEA, in the SAT of obese individuals, with or
without T2D, and in NW subjects. Although several
other congeners of AEA (known as N-acylethanolamines)
and 2-AG (the monoacylglycerols) occur in tissues, we
quantified here AEA, OEA, PEA and 2-AG because these
are the most studied members of their families of lipids,
the molecular target of which are also more relevant to
the pathophysiology of energy metabolism.
Possible significance of the observed alterations of the 
concentrations of endocannabinoids and related lipids in 
the SAT of OBT2D patients
In the only study published to date in which endocannab-
inoid levels have been measured in the SAT of obese
Figure 1 Differential alterations of endocannabinoid, oleoyletha-
nolamide and palmitoylethanolamide levels in the subcutaneous 
adipose tissue of normoweight, obese and type 2 diabetes obese 
subjects. Endocannabinoid levels (in pmol/g tissue, means ± SE) were 
measured in the subcutaneous adipose tissue in individuals with obe-
sity and diabetes (N = 10), only obesity (N = 11), and normal weight 
controls (N = 8). AEA = anandamide (arachidonoylethanolamide); 2-AG 
= 2-arachidonoylglycerol; OEA = oleoylethanolamide; PEA = palmi-
toylethanolamide. ANOVA and LSD (Kruskal-Wallis for 2-AG) *p < 0.05, 
**p < 0.001 vs. Control and Obese.
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sponding values in matched NW volunteers, and we have
confirmed here this finding. However, we have also found
that, in the presence of T2D, obese patients do exhibit
differential alterations of the SAT concentrations of the
four measured lipid mediators. In fact, whilst the SAT
levels of the endocannabinoid AEA and of the PPARα
ligands OEA and PEA were significantly higher in
OBT2D, those of the other, more abundant, endocannab-
inoid, 2-AG, were lower. OEA and PEA activate PPARα
receptors with high and intermediate potency, respec-
tively, but are inactive at cannabinoid receptors [26].
Therefore, the SAT of OBT2D subjects might be charac-
terized by a relatively decreased activity of CB1 receptors,
and strongly increased activity of PPARα receptors, as
compared to that of OB and NW subjects. Given the pro-
and anti-lipogenic effects of CB1 and PPARα receptor
activation, respectively [3,27], it is tempting to hypothe-
size that this alteration in the activity of the two receptors
might be partly responsible for the decreased subcutane-
ous vs. visceral fat observed in OBT2D patients [28].
Possible explanations for the observed differential 
alterations of endocannabinoid levels in the SAT of OBT2D 
patients
It is not unusual that AEA and 2-AG tissue concentra-
tions change in different, or even opposing, ways in phys-
iological and pathological conditions, and in both
laboratory animals and humans [29]. This probably
reflects the fact that the two compounds might also play
different roles, particularly as AEA is known to interact
also with non-cannabinoid receptors, including transient
receptor potential vanilloid type-1 channels [30] and, at
higher concentrations, PPAR-γ [31], whereas 2-AG is
more selective for cannabinoid receptors. Furthermore,
AEA, OEA, and PEA share similar biosynthetic and inac-
tivation pathways and enzymes (including FAAH) [32],
which might explain why the levels of these three com-
pounds were found here to be positively correlated with
each other and were altered in the same way in the SAT of
OBT2D subjects. The formation and degradation of 2-
AG is, instead, catalysed by other enzymes [32]. Interest-
ingly, by acting as competing substrates for FAAH, OEA
Table 2: Relationship between endocannabinoid levels in adipose tissue (expressed as pmol/g tissue) and metabolic 
measurements in all subjects participating in the study (Pearson correlation coefficients).
AEA 2-AG OEA PEA
AEA -.10 .76*** .87***
2-AG .32 .09
OEA .87***
Plasma triglycerides .27 -.11 .25 .26
HDL cholesterol -.53** .10 -.48** -.47**
Plasma leptin -.19 -.16 -.09 -.12
Leptin mRNA in SAT .44* .18 .70*** .62***
LPL activity in SAT -.53** .30 -.50** -.48**
Insulin sensitivity (M 
value)
-.32 .50** -.17 -.19
FFA during 
hyperinsulinaemic 
clamp
.47* -.05 .55** .57***
* p < 0.05, ** p < 0.01, *** p < 0.001
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and hence affect endocannabinoid tone. Finally, the dif-
ferent availability of precursor fatty acid pools can differ-
entially affect the levels of N-acylethanolamines and
monoacylglycerols, including AEA and 2-AG [33], and
this can also explain differential changes in levels of the
two endocannabinoids in the three populations studied.
Indeed, it was previously described that there are altera-
tions in arachidonic acid metabolism in obesity [34], and
since arachidonic acid is a precursor to inflammatory
eicosanoids, and inflammation is generally increased in
obesity and diabetes, this could also account for an
altered availability of arachidonic acid for endocannabi-
noid production.
Possible meaning of the observed correlations between 
SAT levels of endocannabinoids or related lipids and 
various biochemical parameters
Previous observations show that: 1) in nonobese, but not
in obese, individuals, insulin negatively controls AEA
more significantly than 2-AG blood levels [8], possibly by
stimulating the expression of FAAH [6], which is more
specific for AEA than 2-AG; and 2) circulating leptin lev-
els are negatively associated with blood AEA, but not 2-
AG, levels in lean, but not in obese, women with eating
disorders [35], although leptin reduces both AEA and 2-
AG levels in mouse adipocytes [3]. In the present study
OBT2D subjects had lower circulating leptin than OB
subjects. This indicates that the increase in SAT AEA lev-
els (and, possibly, also OEA and PEA), observed in
OBT2D subjects was more related to the lower leptin lev-
els than to the level of whole body insulin resistance,
which was instead similar between the two obese groups.
Interestingly, however, the concentrations of AEA, OEA
and PEA, did not correlate negatively with plasma leptin
levels, nor with M values, but did correlate positively with
SAT leptin mRNA levels. This might suggest a possible
negative feed-back loop of these lipid mediators on their
own levels, exerted by up-regulating the expression and
production of one of their negative effectors. Indeed,
activation of CB1 receptors was shown to stimulate insu-
lin release from both rat and human β-cells [3,36], thus
indicating that such negative feed-back regulations are
not unusual for the ECS. With regard to 2-AG, here posi-
tively correlated with M-values, the reduced whole body
insulin sensitivity cannot explain the reduction of its lev-
els in the SAT of OBT2D subjects, since these subjects
exhibited M-values similar to those of OB subjects. This
does not exclude other effects of reduced insulin sensitiv-
ity at any other level in the SAT of OBT2D subjects.
OBT2D subjects had lower adipose tissue LPL activity
than the matched OB or NW subjects. It has been shown
that LPL in adipocytes is stimulated by the activation of
CB1 receptors [37]. Therefore, since SAT LPL activity
here correlated negatively with SAT AEA (and OEA or
PEA) levels, while 2-AG levels showed an opposite ten-
dency, it is possible to hypothesize, again, that increased
AEA might not result in increased SAT CB1 activity,
whereas decreased levels of 2-AG in the SAT might be
partly responsible, via the corresponding reduction of
CB1 activity, for the decreased LPL activity observed in
this adipose depot. This hypothesis would be in agree-
ment also with the very recent finding of reduced CB1
receptor mRNA expression in the SAT of both obese [38]
and overweight dysmetabolic subjects [39], and with
mounting evidence that CB1 receptor tone is reduced in
the SAT of obese animals [13,14].
The SAT concentrations of AEA, but not 2-AG, corre-
lated with decreased HDL cholesterol, which is the oppo-
site of what previously reported for the plasma levels of 2-
AG, which, unlike plasma AEA levels, are correlated with
decreased HDL cholesterol [10-12]. The SAT concentra-
tions of AEA also correlated with a biomarker that is usu-
ally linked with increased lipogenesis in the liver, i.e.
plasma FFA during hyperinsulinaemic clamp. Therefore,
it cannot be excluded that some of the metabolic dys-
functions observed in OBT2D subjects, which might be
caused by overactivation of CB1 receptors, are also due to
elevated AEA concentrations in the SAT. This, in turn,
might lead to the release of this endocannabinoid in the
circulation and to its action on other target tissues (e.g.
the liver), in which CB1 receptor expression/function is
not reduced. In this study we did not measure the levels
of AEA and 2-AG in other tissues or in the plasma. A pre-
vious study carried out in post-menopausal obese women
showed that increased plasma endocannabinoids levels
correlate with decreased FAAH mRNA expression in the
SAT [9], which, in turn, should result in increased SAT
endocannabinoid levels. However, in viscerally obese
men, only increased plasma 2-AG levels correlated with
decreased FAAH mRNA expression in the SAT [10]. Fur-
thermore, plasma 2-AG, but not AEA, levels are signifi-
cantly increased in the plasma of OBT2D vs. OB or T2D
male subjects (V. Di Marzo and L. Van Gaal, unpublished
observations). Therefore, in obese subjects such as those
investigated in the present study, little correlation is likely
to exist between circulating and SAT endocannabinoid
levels. In this respect, the decrease in 2-AG concentra-
tions found here in the SAT of OBT2D subjects is in con-
trast with the increase in circulating 2-AG levels,
observed previously in overweight T2D patients [3]. Also
the aforementioned positive correlation between SAT 2-
AG levels and M-values is in contrast with what observed
with plasma 2-AG levels in obese subjects [8,10]. In fact,
SAT and plasma 2-AG levels seem to predict in opposing
ways insulin resistance and T2D. Likewise, although both
SAT (this study) and blood [3] AEA concentrations are
elevated in T2D patients, the amounts of FFA during
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AEA (this study) and negatively with blood AEA [10].
Conclusions
The concentrations of endogenous lipid mediators that
exert their biological actions by activating either CB1 or
PPARα receptors are altered in the SAT of OBT2D, but
not of simply obese, individuals. Based on our current
knowledge of the role of the ECS in the WAT [1,4,5], such
alterations might contribute to less fat accumulation in
the SAT relative to VAT, and to some metabolic altera-
tions that, along with impaired insulin release and sensi-
tivity, are typical of obese patients with T2D [40,41].
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